PATRICK G ENRIGHT
CIK 1253886 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.03B
Companies
17
Total Filings
153
Lifetime Open-Market Net
-$89.38M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBIO | Director | 1,844,659 | $31.00 | $57.18M | $9.73M | 4 | 2026-06-17 |
| BIOA | Director | 1,310,589 | $22.00 | $28.83M | $7.20M | 3 | 2026-06-12 |
| VERA | Director | 3,602,475 | $32.63 | $117.55M | $32.53M | 11 | 2026-05-26 |
| MANE | Director | 2,407,752 | $108.34 | $260.86M | $18.27M | 1 | 2026-02-05 |
| JAZZ | Director | 21,379 | $254.86 | $5.45M | -$228.70M | 64 | 2026-01-08 |
| Aptinyx Inc. (APTX) Delisted | Director | 3,451,746 | $0.06 | $210.6K | $3.19M | 14 | 2022-05-31 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 5,611 | $54.99 | $308.5K | $0 | 1 | 2022-04-29 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 195,935 | $2.57 | $503.6K | $12.60M | 1 | 2020-10-22 |
| COLL | Director | 0 | $36.17 | $0 | $1.92M | 11 | 2020-10-14 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,007,225 | $4.00 | $8.03M | $40.00M | 1 | 2020-07-28 |
| 89bio, Inc. (ETNB) Delisted | 10%+ Owner | 2,600,877 | $14.84 | $38.60M | $48.80M | 2 | 2020-07-14 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 279,902 | $0.00 | $28 | $29.98M | 1 | 2019-11-27 |
| Axonics, Inc. (AXNX) Delisted | 10%+ Owner | 2,933,333 | $70.98 | $208.21M | $24.00M | 1 | 2018-11-02 |
| KALA | 10%+ Owner | 823 | $0.70 | $575 | $12.90M | 1 | 2017-07-27 |
| CORT | Director | 5,993,653 | $92.27 | $553.03M | -$43.10M | 26 | 2017-03-20 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 7,467,694 | — | — | $10.45M | 3 | 2016-03-31 |
| ESPR | Director | 1,119,256 | $3.18 | $3.56M | -$69.15M | 6 | 2015-05-18 |
Recent Filings · Page 8 of 16
153 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-20 | CORT | Sell (S) | −269,955 | -$2.68M | EDGAR |
| 2017-03-15 | CORT | Sell (S) | −600,000 | -$6.09M | EDGAR |
| 2017-03-10 | CORT | Sell (S) | −750,000 | -$7.31M | EDGAR |
| 2017-02-27 | CORT | Sell (S) | −2,500,000 | -$22.02M | EDGAR |
| 2016-12-14 | CORT | Other (J) | +204,210 | $0 | EDGAR |
| 2016-12-06 | JAZZ | Sell (S) | −677 | -$68.9K | EDGAR |
| 2016-12-01 | COLL | Other (J) | −1,492,724 | $0 | EDGAR |
| 2016-11-30 | CORT | Other (J) | −3,000,000 | $0 | EDGAR |
| 2016-11-25 | CORT | Sell (S) | −36,941 | -$345.2K | EDGAR |
| 2016-11-21 | CORT | Sell (S) | −544,100 | -$5.20M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.